Herbal Therapeutics in Inflammatory Bowel Disease

Herbal therapeutics have emerged as a complementary strategy in the management of inflammatory bowel disease (IBD), encompassing both Crohn’s disease and ulcerative colitis. Traditional botanical preparations such as indigo naturalis and Qing-dai powder are rich in bioactive alkaloids, flavonoids and terpenoids that exert anti-inflammatory, antioxidant and mucosal-healing effects. Advances in network pharmacology have elucidated multi-target interactions, implicating pathways such as NF-κB, Jak-STAT and toll-like receptors. In parallel, studies of gut microbiota modulation reveal that certain herbal compounds foster the growth of short-chain fatty acid-producing bacteria, restoring microbial balance and barrier integrity. Collectively, this body of work highlights the global significance of phytochemical approaches as adjuncts or alternatives to conventional immunosuppressive and biologic therapies, offering novel avenues for personalised treatment and reduced adverse profiles.

Research from Nature Portfolio

Recent studies have dissected the molecular underpinnings of indigo naturalis in ulcerative colitis models. By integrating transcriptomic profiling with network pharmacology, researchers identified key active constituents that engage a protein–protein interaction network of immune and epithelial targets. Enrichment analyses highlighted modulation of Th17 differentiation, IL-17 and Jak-STAT signalling, as well as toll-like and NOD-like receptor pathways. This systems-level approach has provided a theoretical framework for isolating core alkaloids and optimising dosage forms, thereby advancing rational development of herbal formulations with enhanced efficacy and safety.

Herbal Therapeutics in Inflammatory Bowel Disease publication trend

The graph below shows the total number of articles in herbal therapeutics in inflammatory bowel disease across all publications each year (not limited to Nature Index journals).

Technical terms

Inflammatory bowel disease (IBD): Chronic inflammatory disorders of the gastrointestinal tract, primarily Crohn’s disease and ulcerative colitis.

Network pharmacology: An analytical approach that maps interactions between multiple herbal constituents and molecular targets to elucidate therapeutic mechanisms.

Dextran sulfate sodium (DSS): A chemical agent used to induce colitis in animal models by disrupting the intestinal epithelial barrier.

NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells): A transcription factor central to the regulation of inflammatory responses.

TLR4/MyD88 pathway: A toll-like receptor signalling route that activates innate immunity and pro-inflammatory cytokine production.

Short-chain fatty acids (SCFAs): Metabolites produced by gut microbiota that support epithelial health and modulate immune function.

References

1. Mechanisms of indigo naturalis on treating ulcerative colitis explored by GEO gene chips combined with network pharmacology and molecular docking. Scientific Reports (2020).
2. Qing-dai powder promotes recovery of colitis by inhibiting inflammatory responses of colonic macrophages in dextran sulfate sodium-treated mice. Chinese Medicine (2015).
3. Indigo Naturalis Alleviates Dextran Sulfate Sodium-Induced Colitis in Rats via Altering Gut Microbiota. Frontiers in Microbiology (2020).
4. Tryptanthrin Protects Mice against Dextran Sulfate Sodium-Induced Colitis through Inhibition of TNF-α/NF-κB and IL-6/STAT3 Pathways. Molecules (2018).
5. Exploring the Mechanism of Indigo Naturalis in the Treatment of Ulcerative Colitis Based on TLR4/MyD88/NF-κB Signaling Pathway and Gut Microbiota. Frontiers in Pharmacology (2021).
6. Botanical Drugs as an Emerging Strategy in Inflammatory Bowel Disease: A Review. Mediators of Inflammation (2015).